Amanta Healthcare Reports Strong Q2 FY27 Growth and Commissioning of SteriPort Line 3
Amanta Healthcare Ltd · Investor Presentation · 04 Nov 2026, 5:33 pm
Amanta Healthcare Reports Strong Q2 FY27 Growth and Commissioning of SteriPort Line 3 Amanta Healthcare posted Q2 FY27 revenue of ₹83.13 Cr, up 17.3% YoY, with EBITDA at ₹17.95 Cr (21.6% margin) and PAT rising 303% YoY to ₹4.86 Cr. H1 FY27 revenue reached ₹151.94 Cr with PAT of ₹8.17 Cr. SteriPort Line 3 was commissioned in early Sep'26, expanding capacity by 75% to 11.6 Cr bottles and targeting ~₹60 Cr FY27 revenue. Upcoming SVP expansion in Q1 FY28 will boost capacity to 31.7 Cr units, supporting management's medium-term target of 20%+ revenue CAGR and 25%+ EBITDA margin.
Original exchange filing (PDF)
More announcements from Amanta Healthcare Ltd
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vishal Ashokkumar Patel · 18 Nov 2026
- submission of Disclosures under Regulation 7(2) of The SEBI (Prohibition of Insider Trading) Regulations, 2015 - off-market transfer of equity shares · 18 Nov 2026
- Company Response On The Spurt In Volume Of Security Across Exchanges · 14 Nov 2026
- The Exchange has sought clarification from Amanta Healthcare Ltd on November 13, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited. · 13 Nov 2026
- Transcript of Post Results Conference call held on November 4, 2026 · 09 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jitendrakumar Jashbhai Patel · 09 Nov 2026
- submission of Disclosure under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 (the "Insider Trading Regulations") · 07 Nov 2026
- submission of Audio Recording of Post Results Conference Call held on November 4, 2026 · 04 Nov 2026
